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Introduction {#sec001}
============

Fervent efforts are underway to develop novel antibiotics to subdue growing bacterial resistance. Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor with activity against imipenem non-susceptible *Pseudomonas* species as well as KPC-producing *Enterobacteriaceae* \[[@pone.0233335.ref001],[@pone.0233335.ref002]\]. Recently, it was FDA approved for complicated intra-abdominal (cIA)and urinary tract infections (cUTI) under the brand name Recarbrio^®^. A recently published phase III study, The RESTORE IMI-1 demonstrated safety and tolerability in patients infected with carbapenem non-susceptible bacterial pathogens \[[@pone.0233335.ref003]\]. A press release \[[@pone.0233335.ref004]\] announced that the RESTORE IMI-2, a phase 3 study in hospital-acquired and ventilator associated bacterial pneumonia has met the primary endpoint.

Optimization of antimicrobials based on pharmacokinetics/pharmacodynamics (PK/PD) is critical in hospitalized patients and especially in critically ill ones. Intravenous (IV) antimicrobials should be infused through separate peripheral lines, different central line lumens, or staggered based on priority, infusion time, and dosing intervals to attain the PK/PD outcomes \[[@pone.0233335.ref005]\]. The separation process requires extensive attention, critical thinking, and could consume a significant amount of healthcare providers' time.

The availability of y-site compatibility data between potentially co-administered intravenous antimicrobials would contribute to direct cost savings, reduce nursing time, and enhance the clinical utility in health care settings. We sought to assess the physical compatibility of imipenem/cilastatin/relebactam, when diluted for infusion in suitable diluent; sodium chloride 0.9% (NS) and dextrose 5% in water (D5W) solutions for injection during simulated Y-site administration with common parenteral IV antimicrobials to assist clinicians and stewardship programs with drug administration protocols.

Methods {#sec002}
=======

Study test agents {#sec003}
-----------------

Imipenem/cilastatin/relebactam drug product vials for injection was supplied by Merck & Co Inc, (Kenilworth, NJ, USA) for use during the *in vitro* experiments. Intravenous antimicrobials tested for compatibility with imipenem/cilastatin/relebactam were purchased from a whole sale supplier (McKesson, USA), or from the pharmacy department at Cooper University Health, NJ, USA. The compatibility tests were performed using a two-drug combination at a time, in the intravenous fluid solutions in which both drugs are recommended for administration by their respective manufacturers (either NS or D5W or both separately). The studied drugs were reconstituted for experimentation at the standard concentrations for clinical use for intravenous admixtures, at the upper limit of the concentration range as recommended by the respective manufacturer, or as commercially available at the time of the study. The number of antimicrobials in this study were determined based on: the commonly used ones in practice and the expected co-administration with imipenem/cilastatin/relebactam in consultation with the sponsor. Drug particulars; manufacturer, lot number and expiry date were recorded for each drug.

Reconstitution and preparation {#sec004}
------------------------------

Imipenem/cilastatin/relebactam vials were reconstituted and diluted to the final concentration 5mg/mL as recommended by the manufacturer. The study intravenous drugs were compounded in appropriate diluent(s) or undiluted as outlined in each of the drug's monograph. The resulting solutions were prepared immediately prior to the experimentation and refrigerated at (2 to 8°C) and/or light protected by wrapping in aluminum foil, if recommended in the drug monograph.

Simulated Y-site administration {#sec005}
-------------------------------

A 5mL sample of imipenem/cilastatin/relebactam at the desired concentration (5mg/mL) was combined with a 5 mL sample of each of the tested intravenous drug solutions in a colorless, 15-mL, borosilicate glass, screw-cap culture tube with polypropylene caps to simulate the inline mixing through a Y-injection site in a 1:1 ratio \[[@pone.0233335.ref006], [@pone.0233335.ref007]\]. Each of the sample solutions passed through a 0.22-μm filter syringe as it is introduced into the culture tube. Each combination was prepared in duplicate, reversing the order of component addition between the two samples so that there are four vials containing the mixture (n = 2 for each order prepared).

Visual inspection {#sec006}
-----------------

Visual inspection and turbidity assessments were conducted as detailed in the following text. After mixing, samples were visually inspected with an unaided eye under normal fluorescent light against black and white backgrounds at 0, 15, 60- and 120-minute intervals. Samples were then stored at room temperature (range 20-25°C), under constant fluorescent light throughout the mixing and until the end of the experiment (2 hours). Combinations were further inspected by passing a direct laser pointer beam through the borosilicate culture tubes to garner a Tyndall effect should any particulate matter forms. Incompatibility was also observed if there was any visible particulate matter, haze, or color changes. For drugs that are typically administered by intravenous bolus or rapid infusion, testing was done at 0, 15, 60 and 120 -minutes intervals only.

Turbidity assessments {#sec007}
---------------------

Sample turbidity was measured through laboratory-grade turbidimeter (Hach, USA) in 10 mL borosilicate glass tubes according to the operating instructions. The original storage tube was gently inverted three times, and then a 5 mL from each vial above was transferred to the 10 mL tube for turbidity assessment. Determinations were made for samples at 0, 15, 60 and 120 -minute intervals after mixing. Physical incompatibility was defined as a change in measured turbidity of ≥ 0.5 nephelometric turbidity units (NTU) \[[@pone.0233335.ref008], [@pone.0233335.ref009]\]. Duplicate test combinations were prepared for evaluation at the same time point of as used for the other drugs (0, 15, 60 and 120 -minutes intervals after mixing), reversing the order of drug addition into each pair of test tubes. Samples were stored at room temperature (20 to 25 C) in normal laboratory fluorescent light, as previously described \[[@pone.0233335.ref010]\].

Assessment of pH {#sec008}
----------------

At the same time points described above (0, 15 min, 60 and 120 -minute intervals after mixing) and prior to mixing (imipenem/cilastatin/relebactam control), sample pH was determined in triplicate for each mixture in the 10 mL borosilicate tube with a laboratory grade pH meter (Fischer Scientific, USA). The wide pH changes were utilized to confirm any physical incompatibilities that may have been observed via Tyndall effect and turbidity measurement. Additionally, if the pH of a mixture that fell outside of the range which is considered safe for intravenous administration (pH: 4--9), was reported as such.

Experimental controls {#sec009}
---------------------

Control solutions (negative) were prepared in borosilicate glass tubes with 5 mL of imipenem/cilastatin/relebactam solution and passed through a 0.22-μm filter in a filter syringe, while it is introduced into the culture tube. An additional 5 mL of the diluting solution was added to simulate test sample preparation in 1:1 ratio with reversing the order of addition. Control solutions for phenytoin and haloperidol (D5W only) were prepared as explained above to establish a positive control.

Results {#sec010}
=======

A collection of antimicrobial agents was tested for Y- site compatibility with imipenem/cilastatin/relebactam. ([Table 1](#pone.0233335.t001){ref-type="table"}) Twenty five antimicrobials were tested in normal saline and 22 antimicrobials were tested in D5W, as diluent solutions depending on individual product-diluent compatibility. After admixture with imipenem/cilastatin/relebactam, tested admixed solutions were clear, colorless, and with no demonstrable haze, except for the following drugs; amphotericin B, doxycycline, levofloxacin, tigecycline (yellow color), and posaconazole (white, hazy and turbid solution). Tyndall effect was observed only in the posaconazole admixed solution. Observations were the same in both diluents. ([Table 2](#pone.0233335.t002){ref-type="table"})

10.1371/journal.pone.0233335.t001

###### Imipenem/cilastatin/relebactam compatibility with tested antimicrobials.

![](pone.0233335.t001){#pone.0233335.t001g}

  Drug                                Concentration[\*](#t001fn001){ref-type="table-fn"} (mg/mL)   NS       D5W
  ----------------------------------- ------------------------------------------------------------ -------- --------
  Acyclovir                           7                                                            Comp     Comp
  Amikacin sulfate                    10                                                           Comp     Comp
  Amphotericin B deoxycholate         0.25                                                         N/A      Incomp
  Ampicillin/sulbactam                20+10                                                        Comp     N/A
  Anidulafungin                       0.77                                                         Comp     N/A
  Azithromycin                        2                                                            Comp     Comp
  Aztreonam                           20                                                           Comp     Comp
  Caspofungin                         0.5                                                          Comp     N/A
  Ceftolozane/tazobactam              10+5                                                         Comp     Comp
  Clindamycin                         12                                                           Comp     Comp
  Colistimethate sodium               4.5                                                          Comp     Comp
  Doxycycline hyclate                 1                                                            Comp     Comp
  Fluconazole                         2                                                            Comp     Comp
  Gentamicin sulfate                  5                                                            Comp     Comp
  Isavuconazole                       1.5                                                          Comp     Comp
  Levofloxacin                        5                                                            Comp     Comp
  Linezolid                           2                                                            Comp     Comp
  Metronidazole                       5                                                            Comp     Comp
  Micafungin sodium                   4                                                            Comp     Comp
  Moxifloxacin                        1.6                                                          Comp     Comp
  Plazomicin                          24                                                           Comp     Comp
  Polymyxin B                         1667U/mL                                                     N/A      Comp
  Posaconazole                        2                                                            Incomp   Incomp
  Tedizolid                           0.8                                                          Comp     N/A
  Tigecycline                         1                                                            Comp     Comp
  Tobramycin sulfate                  5                                                            Comp     Comp
  Vancomycin                          10                                                           Comp     Comp
  Voriconazole                        5                                                            Comp     Comp
  Imipenem/cilastatin/relebactam^a^   5                                                            Comp     Comp
  Haloperidol^b^                      5                                                            Incomp   Incomp
  Phenytoin^b^                        5                                                            Incomp   Incomp

\*Concentration expressed in terms of the commercially available form in mg/mL unless otherwise specified

Negative control ^a^

Positive control ^b^

N/A; not applicable, Comp; compatible, Incomp; incompatible

10.1371/journal.pone.0233335.t002

###### Summary of physical characteristics of tested antimicrobials in combination with imipenem/cilastatin/relebactam (same observations in both NS and D5W).

![](pone.0233335.t002){#pone.0233335.t002g}

  Drug                               Black background   White background   Tyndall                  
  ---------------------------------- ------------------ ------------------ --------- -------------- ----------
  Acyclovir                          Clear              None               Clear     Colorless      Negative
  Amikacin sulfate                   Clear              None               Clear     Colorless      Negative
  Amphotericin B deoxycholate        Clear              None               Clear     Light Yellow   Negative
  Ampicillin/sulbactam               Clear              None               Clear     Colorless      Negative
  Anidulafungin                      Clear              None               Clear     Colorless      Negative
  Azithromycin                       Clear              None               Clear     Colorless      Negative
  Aztreonam                          Clear              None               Clear     Colorless      Negative
  Caspofungin                        Clear              None               Clear     Colorless      Negative
  Ceftolozane/tazobactam             Clear              None               Clear     Colorless      Negative
  Clindamycin                        Clear              None               Clear     Colorless      Negative
  Colistimethate sodium              Clear              None               Clear     Colorless      Negative
  Doxycycline hyclate                Clear              None               Clear     Light Yellow   Negative
  Fluconazole                        Clear              None               Clear     Colorless      Negative
  Gentamicin sulfate                 Clear              None               Clear     Colorless      Negative
  Isavuconazole                      Clear              None               Clear     Colorless      Negative
  Levofloxacin                       Clear              None               Clear     Light Yellow   Negative
  Linezolid                          Clear              None               Clear     Colorless      Negative
  Metronidazole                      Clear              None               Clear     Colorless      Negative
  Micafungin sodium                  Clear              None               Clear     Colorless      Negative
  Plazomicin                         Clear              None               Clear     Colorless      Negative
  Polymyxin B                        Clear              None               Clear     Colorless      Negative
  Posaconazole                       Turbid             Hazy               Turbid    White          Positive
  Tedizolid                          Clear              None               Clear     Colorless      Negative
  Tigecycline                        Clear              None               Clear     Yellow         Negative
  Tobramycin sulfate                 Clear              None               Clear     Colorless      Negative
  Vancomycin                         Clear              None               Clear     Colorless      Negative
  Voriconazole                       Clear              None               Clear     Colorless      Negative
  Imipenem/cilastatin/relebactam\*   Clear              None               Clear     Colorless      Negative
  Haloperidol\*\*                    Clear              None               Clear     Light yellow   Negative
  Phenytoin\*\*                      Cloudy             Hazy               Cloudy    Yellow         Positive

Negative control \*

Positive control \*\*

For pH measurements, (Tables [3](#pone.0233335.t003){ref-type="table"} and [4](#pone.0233335.t004){ref-type="table"}), all study solutions were within the range of 4 to 9, with 2 notable exceptions, colistimethate sodium and gentamicin solutions which had some readings slightly below pH value of 4. As per study definition (turbidity increase of ≥ 0.5 NTU), amphoterin B, and posaconazole were found to be incompatible with imipenem/cilastatin/relebactam for simultaneous administration. The admixture of imipenem/cilastatin/relebactam with blank solutions manifested no sign of incompatibility as a negative control while, phenytoin in both NS and D5W and haloperidol in D5W were incompatible yielding readings of ≥ 0.5 NTU and visible development of turbidity as positive controls.

10.1371/journal.pone.0233335.t003

###### Summary of pH changes in the tested antimicrobials over 120 minutes in normal saline.

![](pone.0233335.t003){#pone.0233335.t003g}

  Drug                               NS                     
  ---------------------------------- ------ ------- ------- -------
  Acyclovir                          6.80   -0.07   -0.01   0.03
  Amikacin sulfate                   6.80   -0.38   -0.13   0.07
  Ampicillin/sulbactam               5.97   0.06    -0.30   -0.67
  Anidulafungin                      6.70   -0.12   -0.08   -0.05
  Azithromycin                       5.08   0.26    0.32    0.21
  Aztreonam                          6.17   0.32    0.10    0.08
  Caspofungin                        6.74   -0.13   -0.14   -0.09
  Ceftolozane/tazobactam             6.75   -0.04   -0.02   0.03
  Clindamycin                        6.84   -0.32   -0.32   -0.31
  Colistimethate sodium              6.99   -0.21   -0.23   -0.26
  Doxycycline hyclate                7.89   0.11    0.32    0.17
  Fluconazole                        6.97   -0.27   -0.33   -0.23
  Gentamicin sulfate                 5.18   0.08    -0.08   -0.20
  Isavuconazole                      6.69   -0.28   -0.08   0.02
  Levofloxacin                       5.08   -0.02   0.01    -0.05
  Linezolid                          6.44   -0.78   -0.71   -0.82
  Metronidazole                      5.89   0.06    0.03    0.00
  Micafungin sodium                  6.96   -0.05   0.57    0.01
  Plazomicin                         6.53   -0.31   -0.30   -0.29
  Posaconazole                       6.90   -0.14   -0.22   -0.37
  Tedizolid                          6.17   -0.23   -0.22   -0.32
  Tigecycline                        5.98   0.13    0.08    -0.35
  Tobramycin sulfate                 6.30   -0.42   -0.21   0.25
  Vancomycin                         6.75   -0.02   -0.02   0.01
  Voriconazole                       7.94   0.14    0.35    0.19
  Imipenem/cilastatin/relebactam\*   6.84   0.03    0.1     0.1
  Phenytoin\*\*                      6.75   0.05    0.12    0.06

Negative control \*

Positive control \*\*

10.1371/journal.pone.0233335.t004

###### Summary of pH changes in the tested antimicrobials over 120 minutes in dextrose 5% in water.

![](pone.0233335.t004){#pone.0233335.t004g}

  Drug                               D5W                    
  ---------------------------------- ------ ------- ------- -------
  Acyclovir                          6.57   0.16    0.27    0.78
  Amikacin sulfate                   6.55   0.20    0.34    0.70
  Amphotericin B deoxycholate        6.80   -0.14   -0.10   -0.10
  Azithromycin                       4.81   0.56    0.49    1.29
  Aztreonam                          6.09   0.10    0.51    0.39
  Ceftolozane/tazobactam             6.69   -0.04   0.03    -0.12
  Clindamycin                        7.20   0.09    0.37    0.17
  Colistimethate sodium              4.94   0.97    0.52    1.68
  Doxycycline hyclate                7.62   -0.06   0.17    0.23
  Fluconazole                        5.93   -0.55   -0.55   -0.33
  Gentamicin sulfate                 4.91   0.84    0.51    1.56
  Isavuconazole                      6.44   -0.15   0.40    0.50
  Levofloxacin                       5.09   0.05    0.58    0.77
  Linezolid                          5.87   -0.53   -0.49   -0.45
  Metronidazole                      4.99   -0.06   -0.09   0.07
  Micafungin sodium                  6.52   -0.14   -0.12   -0.70
  Polymyxin B                        5.90   -0.03   0.18    0.23
  Posaconazole                       6.52   -0.35   -0.38   -0.42
  Tigecycline                        5.92   -0.08   0.16    0.18
  Tobramycin sulfate                 6.50   0.19    0.26    0.83
  Vancomycin                         7.40   0.22    0.36    0.34
  Voriconazole                       7.42   -0.22   0.10    0.20
  Imipenem/cilastatin/relebactam\*   6.62   0.21    0.23    0.17
  Haloperidol\*\*                    6.32   0.42    0.5     0.61
  Phenytoin\*\*                      6.3    0.51    0.48    0.6

Negative control \*

Positive control \*\*

Discussion {#sec011}
==========

When tested for y-site administration with a variety of antimicrobial agents comprising a wide spectrum of activity, imipenem/cilastatin/relebactam was incompatible with amphotericin B and posaconazole. Alternatively, the drug was compatible with other antifungals (anidulafungin, micafungin, caspofungin and fluconazole). Additionally, the drug was compatible with several antibacterial agents covering a broad spectrum of bacteria including, both Gram-positive and negative bacteria.

In comparison with the parent compound imipenem/cilastatin, Trissel's (11) reported amphotericin B, ampicillin/sulbactam, azithromycin, aztreonam and fluconazole were reported to be of uncertain compatibility for various reasons. Ampicillin is known to be unstable in dextrose containing solutions, azithromycin in NS formed white microcrystalline precipitate on a 0.8-micron filter when examined microscopically, aztreonam in D5W was compatible at 40 mg/mL and incompatible at 80 mg/mL and fluconazole 2mg/mL precipitated immediately when mixed undiluted \[[@pone.0233335.ref011]\]. However, in our study amphotericin B was found to be incompatible and the above listed antimicrobials were compatible. The dissimilarity could be attributed to different definitions of incompatibility, drug concentrations used in the experiment or discrepant findings of several studies reported to Trissel's \[[@pone.0233335.ref011]\].

It is noteworthy that, since several antimicrobials were previously reported to be incompatible with imipenem/cilastatin \[[@pone.0233335.ref011]\] (amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome, ceftriaxone, daptomycin, ganciclovir, minocycline, quinupristin and dalfopristin, sulfamethoxazole-trimethoprim and temocillin), they were excluded from the current study based on the expected incompatibility with imipenem/cilastatin/relebactam.

A recent study which evaluated simultaneous Y-site administration of similar carbapenem/carbapenemase inhibitor combination (meropenem/vaborbactam), found the compound to be compatible only with one antifungal, micafungin, while it was incompatible with anidulafungin, caspofungin, isavuconazole, and not tested against amphotericin B, fluconazole, posaconazole, voriconazole. Imipenem/cilastatin/relebactam was compatible with several antifungal agents as listed above. Regarding antibiotics with MRSA activity, meropenem/vaborbactam was compatible with linezolid, tedizolid and vancomycin, (incompatible with daptomycin and ceftaroline), comparably, imipenem/cilastatin/relebactam was compatible with linezolid, tedizolid and vancomycin but not tested with neither ceftaroline nor daptomycin. Both compounds were compatible with aminoglycosides (amikacin, gentamicin and tobramycin) in case synergy is required. Finally, imipenem/cilastatin/relebactam was compatible with acyclovir, while meropenem/vaborbactam was not tested with any antiviral agents \[[@pone.0233335.ref012]\].

As a relevant point of comparison, while imipenem/cilastatin/relebactam does not need prolonged infusion time to achieve target *f*T\>MIC (30-min infusion every 6 hours), meropenem/vaborbactam is recommended for 3-hour infusion every 8 hours. In case of unknown compatibility or incompatibility antimicrobial that requires prolonged or continuous infusion, a robust logistic plan must be in place to accommodate the separate administration of the two drugs around the clock.

Antimicrobial stewardship programs aim to provide patients with the most effective treatment, while reducing costs. Simultaneous administration of antibiotics allows; the use of antibiotic combinations for serious infections without the need for dedicated lines, reducing the total time needed for infusion while allowing a window for PK/PD manipulation and shortening nursing time required for administration/observation. The availability of drug compatibility data guides the design of stewardship protocols on which antibiotic combinations can be administered via shared lines and eliminates the need for successive administration, thus producing time and cost savings.

A limitation of this study is that the physical compatibility profile is described for only 120 minutes and possibility of incompatibility beyond that time frame precludes co-administration of imipenem/cilastatin/relebactam with tested intravenous antimicrobials for longer period of time.

Conclusion {#sec012}
==========

The compatibility data generated from this study, will aid clinicians in overcoming difficulties pertinent to successive administration in terms of reducing total infusion time, optimizing PK/PD exposure, by allowing prolonged/extended infusion to be accommodated on top of economizing nursing time, and cost.

We acknowledge the efforts of Jacqueline Sutton Pharm. D., director of pharmacy department at Cooper University Hospital (Camden, NJ, USA) for procuring study products during limited commercially availability periods.

[^1]: **Competing Interests:**The corresponding author, IG received research grant from Merck & Co USA to support this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
